Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2139 participants.

Also called NCT01968967

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,139 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01968967
  • EudraCT 2013-002643-28
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Colombia, France, Hungary, Lithuania, Mexico, Romania, Russia, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01968967. Randomized; quadruple masking; primary purpose treatment. Start 2013-10-29 (actual); primary completion 2016-07-05 (actual). Results posted on 2017-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
Acronym
SPIRE-LDL
Condition
Hyperlipidemia
Intervention (Drug)
Bococizumab (PF-04950615; RN316)
Intervention (Other)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01968967
Content hash
d9fa72ca044844a8faa73fe34ddbafccfc7f2b733ed25e174a0eefaf1e2857ce